BILLERICA, Mass. – Data was presented at the recent American Society of Clinical Oncology’s 2011 Genitourinary Cancers Symposium showing multiple protein biomarkers predictive of clinical benefit and prognostic of disease outcome in patients with advanced or metastatic renal cell cancer. This Phase III trial validated plasma cytokine and angiogenic biomarkers using Aushon’s multiplex immunoassay platform.

The University of Texas MD Anderson Cancer Center also reported results from a Phase II study earlier last year, which demonstrated excellent correlation between Aushon’s platform and the ELISA across multiple biomarkers.

“Until now, the single-plex ELISA has been the ‘gold standard’ for protein biomarker analysis in late stage clinical trials due to its perceived reliability”, said Peter Honkanen, CEO of Aushon. “Data from these Phase II and Phase III studies demonstrate that Aushon’s multiplex technology can perform as well as the ELISA, while providing all the other benefits of a next-generation, multiplex platform including convenience, reduced sample consumption, higher throughput and lower cost performance. This clearly demonstrates that Aushon’s technology has met the stringent expectations in a late stage clinical trial setting where the performance bar is very high.”

About Aushon BioSystems

Aushon BioSystems provides a comprehensive suite of multiplex immunoassay products and services for protein biomarker discovery, development and analysis to leading pharmaceutical, biotechnology, academic and diagnostic clients worldwide. Our unique combination of advanced microarray printing technology, robust biomarker content and an innovative multiplex immunoassay technology platform delivers exceptional performance, quality and reliability that accelerate pre-clinical and clinical biomarker research. Our customers trust us to provide the most reliable protein biomarker data available, which lowers costs and improves research productivity. For more information, please visit www.aushon.com.